DrSalvatoreSantamaria

•Teraz-Orosz A, Gierula M, Petri A, Jones DA, Keniyopoullos R, Badia Folgado P, Santamaria S, Crawley JTB, Lane DA, Ahnstrom J. Laminin G1 residues of protein S mediate its TFPI cofactor function and are competitively regulated by C4BP. Blood Adv. 2021 Nov 3:bloodadvances.2021005382.

•Santamaria S, Martin DR, Dong X, Yamamoto K, Apte SS, Ahnström J. Post-Translational Regulation And Proteolytic Activity Of The Metalloproteinase Adamts8. J Biol Chem. 2021 Oct 20:101323. doi: 10.1016/j.jbc.2021.101323. Epub ahead of print. PMID: 34687701.

•Yamamoto K, de Groot R, Scilabra SD, Kwok HF, Santamaria S. Editorial: ADAM, ADAMTS and Astacin Proteases: Challenges and Breakthroughs in the -Omics Era. Front Mol Biosci. 2021 Oct 12;8:780242.

•Santamaria S, Buemi F, Nuti E, Cuffaro D, De Vita E, Tuccinardi T, Rossello A, Howell S, Mehmood S, Snijders AP, de Groot R. Development of a fluorogenic ADAMTS-7 substrate. J Enzyme Inhib Med Chem. 2021 Dec;36(1):2160-2169. 

•Martin DR, Santamaria S, Koch CD, Ahnström J, Apte SS. Identification of novel ADAMTS1, ADAMTS4 and ADAMTS5 cleavage sites in versican using a label-free quantitative proteomics approach. J Proteomics. 2021 Aug 24:104358.

•Santamaria S (2021) Targeting the PI3K/AKT pathway: a potential new weapon in the global fight against SARS-CoV-2? Int J Biol Sci. 17(11):2770-2771.

•Santamaria S, Cuffaro D, Nuti E, Ciccone L, Tuccinardi T, Liva F, D'Andrea F, de Groot R, Rossello A, Ahnström J. (2021). Exosite inhibition of ADAMTS-5 by a glycoconjugated arylsulfonamide. Sci Rep. 11:949.

•Santamaria S, de Groot R (2020) ADAMTS proteases in cardiovascular physiology and disease. Open Biol.10(12):200333

•Santamaria S (2020) ADAMTS‐5: A difficult teenager turning 20.Int J Exp Pathol   101(1-2):4-20.

•Santamaria S, Yamamoto K (2020) Analysis of Aggrecanase Activity Using Neoepitope Antibodies. Methods Mol Biol. 2020;2043:125-136.

•Santamaria S. (2020) Chemical Modification of Proteoglycanases with Biotin.  Methods Mol Biol. 2020;2043:113-123.

•Santamaria S, Yamamoto K, Teraz-Orosz A, Koch C, Apte SS, de Groot R, Lane DA, Ahnström J. (2019) Exosites in Hypervariable Loops of ADAMTS Spacer Domains control Substrate Recognition and Proteolysis. Sci Rep. 9(1):10914

• Colige A, Monseur C, Crawley JTB, Santamaria S, de Groot R (2019) Proteomic discovery of substrates of the cardiovascular protease ADAMTS7. J Biol Chem.294(20):8037-8045.

•Santamaria S, de Groot R (2019), Monoclonal antibodies against metzincin targets.Br J Pharmacol. 294(20):8037-8045.

• Santamaria S, Nagase H (2018), Measurement of Protease Activities Using Fluorogenic Substrates. Methods Mol Biol. 1731:107-122.

• Santamaria S, Reglinska-Matveyev N, Gierula M, Camire RM, Crawley JTB, Lane DA, Ahnstrom J (2017) Factor V anticoagulant cofactor activity that targets the early phase of coagulation. Journal of Biological Chemistry 292(22):9335-9344.

• Santamaria S, Fedorov O, McCafferty J, Murphy G, Dudhia J, Nagase H, Yamamoto K (2017) Development of a monoclonal anti-ADAMTS-5 antibody that specifically blocks the interaction with LRP1.  MAbs 9(4):595-602.

• Yamamoto K, Santamaria S, Botkjaer KA, Dudhia J, Troeberg L, Itoh Y, Murphy G, Nagase H (2017)  Inhibition of shedding of low-density lipoprotein receptor-related protein 1 reverses cartilage matrix degradation in osteoarthritis. Arthritis Rheumatol. 69(6):1246-1256.

•Nuti E, Cuffaro D, D'Andrea F, Rosalia L, Tepshi L, Fabbi M, Carbotti G, Ferrini S, Santamaria S, Camodeca C, Ciccone L, Orlandini E, Nencetti S, Stura EA, Dive V, Rossello A. (2016), Sugar-based Arylsulfonamide Carboxylates as Selective and Water-Soluble Matrix Metalloproteinase-12 inhibitors.Chem Med Chem. 11(15):1626-37.

•Yamamoto K, Okano H, Miyagawa W, Visse R, Shitomi Y, Santamaria S, Dudhia J, Troeberg L, Strickland DK, Hirohata S, Nagase H. (2016), MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP-1. Matrix Biol. 56:57-73.

•Botkjaer KA, Kwok HF, Terp MG, Karatt-Vellatt A, Santamaria S, McCafferty J, Andreasen PA, Itoh Y, Ditzel HJ, Murphy G. (2016) Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo. Oncotarget. 7, 16773-16792.

•    Santamaria S, Yamamoto K, Botkjaer K, Tape C, Dyson MR, McCafferty J, Murphy G, Nagase H (2015) Antibody-based exosite inhibitors of ADAMTS-5 (Aggrecanase-2). Biochem J. 471, 391-401.

•    Santamaria S, Nuti E, Cercignani G, La Regina G, Silvestri R, Supuran CT, Rossello A.(2015) Kinetic characterization of 4,4'-biphenylsulfonamides as selective non-zinc binding MMP inhibitors. J Enzyme Inhib Med Chem. 230, 947-954.

•    Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C, Orlandini E, Nencetti S, Rossello A. (2013), Selective Arylsulfonamide Inhibitors of ADAM-17: Hit Optimization and Activity in Ovarian Cancer Cell Models. J Med Chem. 56(20):8089-103.

•    Nuti E, Santamaria S (First Joint), Casalini F, Yamamoto K, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Marini AM, Salerno S, Taliani S, Da Settimo F, Nagase H, Rossello A. (2013), Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: Synthesis and biological evaluation. Eur J Med Chem. 62:379-394.

•    Madsen JL, Andersen TL, Santamaria S, Nagase H, Enghild JJ, Skrydstrup T. (2012), Synthesis and Evaluation of Silanediols as Highly Selective Uncompetitive Inhibitors of Human Neutrophil Elastase. J Med Chem. 55(17):7900-8.

•    Santamaria S, Nuti E, Cercignani G, Marinelli L, La Pietra V, Novellino E, Rossello A (2012), N-O-Isopropyl sulfonamido-based hydroxamates: Kinetic characterisation of a series of MMP-12/MMP-13 dual target inhibitors. Biochem Pharmacol. 84(6):813-20.

•    La Pietra V, Marinelli L, Cosconati S, Di Leva FS, Nuti E, Santamaria S, Pugliesi I, Morelli M, Casalini F, Rossello A, La Motta C, Taliani S, Visse R, Nagase H, da Settimo F, Novellino E (2011), Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: A first round of lead optimization. Eur J Med Chem. 47(1):143-52.

•    Marques SM, Tuccinardi T, Nuti E, Santamaria S, André V, Rossello A, Martinelli A, Santos MA. (2011), Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases. J Med Chem. 54(24):8289-98.

•    Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A. (2011), Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem.46(7):2617-29.

•    Carrasco MP, Enyedy EA, Krupenko NI, Krupenko SA, Nuti E, Tuccinardi T, Santamaria S, Rossello A, Martinelli A, Santos MA. (2011), Novel Folate-Hydroxamate Based Antimetabolites: Synthesis and Biological Evaluation .Medicinal Chemistry 7(4):265-74.

•    Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A. (2010), Potent Arylsulfonamide Inhibitors of Tumor Necrosis Factor-alpha Converting Enzyme Able to Reduce Activated Leukocyte Cell Adhesion Molecule Shedding in Cancer Cell Models. J Med Chem. 53(6):2622-35.

•    Nuti E, Panelli L, Casalini F, Avramova SI, Orlandini E, Santamaria S, Nencetti S, Tuccinardi T, Martinelli A, Cercignani G, D’Amelio N, Maiocchi A, Uggeri F, and Rossello A (2009)  Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors. J. Med. Chem. 52, 6347–6361.

•    Nuti E, Casalini F, Avramova SI, Santamaria S, Cercignani G, Marinelli L, La Pietra V, Novellino E, Orlandini E, Nencetti S, Tuccinardi T, Martinelli A, Lim NH, Visse R, Nagase H, Rossello A. N-O-Isopropyl Sulfonamido-Based Hydroxamates: Design, Synthesis and Biological Evaluation of Selective Matrix Metalloproteinase-13 Inhibitors as Potential Therapeutic Agents for Osteoarthritis. J Med Chem. 2009 52(15):4757-73.